Similar articles

• Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.

  Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ. Palmer JL, et al. Adv Ther. 2008 Aug;25(8):752-74. doi: 10.1007/s12325-008-0080-4. Adv Ther. 2008. PMID: 18704282
• Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.

  Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L. Yang W, et al. Diabetes Care. 2008 May;31(5):852-6. doi: 10.2337/dc07-1992. Epub 2008 Feb 11. Diabetes Care. 2008. PMID: 18268073 Clinical Trial.
• Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.

  Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ. Clements MR, et al. Diabetes Obes Metab. 2008 Mar;10(3):229-37. doi: 10.1111/j.1463-1326.2006.00687.x. Diabetes Obes Metab. 2008. PMID: 18269638 Clinical Trial.
• When oral agents fail: optimizing insulin therapy in the older adult.

  Meece J. Meece J. Consult Pharm. 2009 Jun;24 Suppl B:11-7. Consult Pharm. 2009. PMID: 19555131 Review.
• Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes.

  Garg S, Kelly WC, Garg S. Garg S, et al. Expert Rev Med Devices. 2008 Mar;5(2):113-23. doi: 10.1586/17434440.5.2.113. Expert Rev Med Devices. 2008. PMID: 18331174 Review.